248 related articles for article (PubMed ID: 19419553)
21. Comparison of EuroQol-5D and short form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study.
Leung YY; Png ME; Wee HL; Thumboo J
J Rheumatol; 2013 Jun; 40(6):859-65. PubMed ID: 23504382
[TBL] [Abstract][Full Text] [Related]
22. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
23. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
[TBL] [Abstract][Full Text] [Related]
24. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain.
Obradovic M; Lal A; Liedgens H
Health Qual Life Outcomes; 2013 Jul; 11():110. PubMed ID: 23815777
[TBL] [Abstract][Full Text] [Related]
25. Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.
Lamu AN; Björkman L; Hamre HJ; Alræk T; Musial F; Robberstad B
Health Qual Life Outcomes; 2021 Apr; 19(1):125. PubMed ID: 33865400
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.
Kularatna S; Senanayake S; Gunawardena N; Graves N
BMJ Open; 2019 Feb; 9(2):e024854. PubMed ID: 30772857
[TBL] [Abstract][Full Text] [Related]
27. EQ-5D and SF-6D health utility scores in patients with spinal and bulbar muscular atrophy.
Xu RH; Lu M; Zhang S; Dong D
Eur J Health Econ; 2023 Nov; 24(8):1399-1410. PubMed ID: 36418784
[TBL] [Abstract][Full Text] [Related]
28. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.
Shiroiwa T; Fukuda T; Ikeda S; Igarashi A; Noto S; Saito S; Shimozuma K
Qual Life Res; 2016 Mar; 25(3):707-19. PubMed ID: 26303761
[TBL] [Abstract][Full Text] [Related]
29. Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.
Nikl A; Janssen MF; Jenei B; Brodszky V; Rencz F
Pharmacoeconomics; 2024 May; 42(5):583-603. PubMed ID: 38416366
[TBL] [Abstract][Full Text] [Related]
30. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of Chinese medicine quality of life assessment scale (CQ-11D) and EQ-5D-5L and SF-6D scales based on Chinese population.
Zhou J; Xu L; Pan J; Wang M; Zhou P; Wang W; Lu S; Zhu W
Qual Life Res; 2024 Jan; 33(1):113-122. PubMed ID: 37695478
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
Xie S; Wang D; Wu J; Liu C; Jiang W
Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
[TBL] [Abstract][Full Text] [Related]
33. A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A; Mayo NE
Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the EQ-5D-3L and the SF-6D (SF-12) contemporaneous utility scores in patients with cardiovascular disease.
Kularatna S; Byrnes J; Chan YK; Ski CF; Carrington M; Thompson D; Stewart S; Scuffham PA
Qual Life Res; 2017 Dec; 26(12):3399-3408. PubMed ID: 28766084
[TBL] [Abstract][Full Text] [Related]
35. Comparison between EQ-5D and SF-6D utility in rural residents of Jiangsu Province, China.
Jin H; Wang B; Gao Q; Chao J; Wang S; Tian L; Liu P
PLoS One; 2012; 7(7):e41550. PubMed ID: 22848526
[TBL] [Abstract][Full Text] [Related]
36. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey.
Jankowska A; Młyńczak K; Golicki D
Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271
[TBL] [Abstract][Full Text] [Related]
37. Mapping between the Roland Morris Questionnaire and generic preference-based measures.
Khan KA; Madan J; Petrou S; Lamb SE
Value Health; 2014 Sep; 17(6):686-95. PubMed ID: 25236992
[TBL] [Abstract][Full Text] [Related]
38. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
Adams R; Walsh C; Veale D; Bresnihan B; FitzGerald O; Barry M
Pharmacoeconomics; 2010; 28(6):477-87. PubMed ID: 20465316
[TBL] [Abstract][Full Text] [Related]
39. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
Whitehurst DG; Norman R; Brazier JE; Viney R
Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
[TBL] [Abstract][Full Text] [Related]
40. A comparison of four different approaches to measuring health utility in depressed patients.
Turner N; Campbell J; Peters TJ; Wiles N; Hollinghurst S
Health Qual Life Outcomes; 2013 May; 11():81. PubMed ID: 23659557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
